Headquartered in Edinburgh, Aridhia was founded in 2008 by entrepreneur Dr David Sibbald OBE and Professor Andrew Morris, Dean and Professor of Medicine at the University of Dundee, Scotland. Aridhia has built a informatics platform with analytical tools to support health care and research. The platform uses big data analytics to understand the relationship between healthcare events and serves the effective management of chronic diseases and the shift to stratified medicine in the future.
Aridhia’s client base includes the Ministry of Health of Kuwait, NHS Scotland, several Academic Health Science Networks in the UK and other healthcare providers internationally. Its network of strategic partners includes Pivotal, a leading provider of application and data infrastructure software; and global life sciences company, Life Technologies, with which Aridhia is collaborating to support the Stratified Medicine Scotland Innovation Centre.
Dr Andrew Elder, partner and head of healthcare at Albion Ventures, said, “We are delighted to be investing in Aridhia, a high growth business that is ideally placed to benefit from the increasingly urgent need to combat chronic disease, the shift to stratified medicine and the application of ‘big data’ analysis. We have invested in the healthcare IT space for several years and Aridhia represents one of the best opportunities we have seen to date in the sector. Aridhia benefits from a strong, proven team and a platform that has been validated by several high quality customers and collaboration partners. We are delighted to be partnering with the team and look forward to supporting its continued growth.”
Jan Rutherford, partner at SEP, added, “Aridhia is the leading European company in its field. As chronic disease is increasing in prevalence globally, we are delighted to continue to support the business as it rolls out its core platform of ground breaking informatics and analytics services.”
Albion Ventures specialises in VCTs with around £230m under management. Aridhia marks Albion’s thirteenth investment in the healthcare sector in the last five years. Other investments include Abcodia, Dysis Medical, Masters Pharmaceuticals, Mirada Medical, MyMeds&Me, Oxford Immunotec, Peakdale Molecular, Proveca and Xceleron.
Copyright © 2013 AltAssets